(3S)-3-[(pyrrolidin-1-yl)carbonyl]piperidine

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (3S)-3-[(pyrrolidin-1-yl)carbonyl]piperidine
• 英文别名: (3S)-3-(pyrrolidine-1-carbonyl)piperidine；[(3S)-piperidin-3-yl]-pyrrolidin-1-ylmethanone
• 化学式: C₁₀H₁₈N₂O
• mdl: MFCD05865122
• 分子量: 182.266
• InChiKey: AMOUVOLDCHVMBJ-VIFPVBQESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  32.3
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF
  申请人：AMGEN INC.

  公开号：US20190077793A1

  公开（公告）日：2019-03-14

  The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising a compound of the invention, a method for manufacturing compounds of the invention and therapeutic uses thereof.

  本发明提供了一种式（I）的化合物或其药学上可接受的盐，包括本发明化合物的药物组合物，制造本发明化合物的方法以及它们的治疗用途。
• HtrA Inhibitors and CagA Inhibitors and Use Thereof
  申请人：PSOMAGEN INC.

  公开号：US20220122691A1

  公开（公告）日：2022-04-21

  The present application relates to new HtrA inhibitors and use thereof. Additionally, the present application also relates to new peptides for inhibiting CagA and use thereof.
• [EN] BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF<br/>[FR] COMPOSÉS ACTIVATEURS DE BISAMIDE SARCOMÈRE ET LEURS UTILISATIONS
  申请人：AMGEN INC

  公开号：WO2019055590A1

  公开（公告）日：2019-03-21

  The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising a compound of the invention, a method for manufacturing compounds of the invention and therapeutic uses thereof.
• [EN] SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS INHIBITORS OF FGFR TYROSINE KINASES<br/>[FR] COMPOSÉS PYRAZOLO[1,5-A]PYRIDINE SUBSTITUÉS SERVANT D'INHIBITEURS DE TYROSINE KINASES FGFR
  申请人：ARRAY BIOPHARMA INC

  公开号：WO2020131627A1

  公开（公告）日：2020-06-25

  Provided herein are compounds of the general Formula I: and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which Ring A, Ring B, Ring C, R1, R2, L, Y, and W have the meanings given in the specification, which are inhibitors of FGFR1, FGFR2, FGFR3 and/or FGFR4 and are useful in the treatment and prevention of diseases which can be treated with an FGFR inhibitor, including diseases or disorders mediated by FGFR1, FGFR2, FGFR3 and/or FGFR4.